We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Palatin Technologies Inc (PTN) USD0.01

Sell:$1.29 Buy:$1.31 Change: $0.07 (5.15%)
Market closed |  Prices as at close on 19 September 2024 | Switch to live prices |
Sell:$1.29
Buy:$1.31
Change: $0.07 (5.15%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 19 September 2024 | Switch to live prices |
Sell:$1.29
Buy:$1.31
Change: $0.07 (5.15%)
Market closed |  Prices as at close on 19 September 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.

Contact details

Address:
4B Cedar Brook Drive
CRANBURY
08512
United States
Telephone:
+1 (609) 4952200
Website:
https://www.palatin.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PTN
ISIN:
US6960775020
Market cap:
$22.11 million
Shares in issue:
16.14 million
Sector:
Biotechnology
Exchange:
-
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Carl Spana
    President, Chief Executive Officer, Director
  • Stephen Wills
    Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.